Certara Inc
NASDAQ:CERT

Watchlist Manager
Certara Inc Logo
Certara Inc
NASDAQ:CERT
Watchlist
Price: 9.22 USD -3.66% Market Closed
Market Cap: 1.5B USD

Certara Inc
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Certara Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Certara Inc
NASDAQ:CERT
Depreciation & Amortization
$68m
CAGR 3-Years
15%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Depreciation & Amortization
$39.6m
CAGR 3-Years
12%
CAGR 5-Years
3%
CAGR 10-Years
21%
Inspire Medical Systems Inc
NYSE:INSP
Depreciation & Amortization
$12.6m
CAGR 3-Years
97%
CAGR 5-Years
76%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Depreciation & Amortization
$10.7m
CAGR 3-Years
29%
CAGR 5-Years
64%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Depreciation & Amortization
$73.7m
CAGR 3-Years
-5%
CAGR 5-Years
5%
CAGR 10-Years
12%
W
Waystar Holding Corp
NASDAQ:WAY
Depreciation & Amortization
$186.6m
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Certara Inc
Glance View

Market Cap
1.5B USD
Industry
Health Care

Certara Inc., founded in 2008, has emerged as a pivotal player in the realm of virtual drug development, leveraging its sophisticated model-based drug development technology to transform how pharmaceutical companies strategize and optimize drug discovery. The company's core strength lies in its comprehensive suite of biosimulation software and services, which predict how drugs behave in the human body. This revolutionary approach allows pharmaceutical companies to refine their drug development processes, increase efficiency, and reduce the time and cost associated with bringing new drugs to market. By providing insights into drug interactions, efficacy, and safety, Certara aids its clients in making informed decisions early in the development cycle, essentially becoming an indispensable ally in navigating the complex and costly landscape of drug development. Certara generates revenue primarily through software licensing and consulting services, establishing long-term partnerships with its diverse clientele, which includes over 1,850 companies worldwide, including prominent pharmaceutical giants and regulatory agencies. By embedding itself into the critical processes of drug development, Certara garners not just the upfront licensing fees but also ongoing consulting fees that allow pharmaceutical companies to fine-tune and optimize their drug development strategies continuously. As healthcare industries place increasing emphasis on precision medicine and personalized healthcare, Certara's role as a guide in these innovations becomes even more pronounced, ensuring its financial health and relevance in a highly competitive field. The company's growth reflects a keen understanding of its niche, capitalizing on its unique offerings to remain at the forefront of scientific innovation.

CERT Intrinsic Value
HIDDEN
Show

See Also

What is Certara Inc's Depreciation & Amortization?
Depreciation & Amortization
68m USD

Based on the financial report for Dec 31, 2024, Certara Inc's Depreciation & Amortization amounts to 68m USD.

What is Certara Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
10%

Over the last year, the Depreciation & Amortization growth was 21%. The average annual Depreciation & Amortization growth rates for Certara Inc have been 15% over the past three years , 10% over the past five years .

Back to Top